US health officials have authorised Eli Lilly’s COVID-19 treatment for a new use in preventing disease in people who have been recently exposed to the virus.
The Food and Drug Administration on Thursday granted emergency use of the drug for adults and children older than 12 who may have an infection and are at high-risk for getting severe COVID-19. Previously the drug was authorized for high-risk patients with confirmed COVID-19. Earlier this summer the FDA authorised preventative use for a similar antibody drug from competitor Regeneron Pharmaceuticals.
Antibody drugs are one of the only treatments proven to reduce the risk of death from COVID-19, especially for people who are not yet in the hospital. Demand for the drugs has boomed as the delta variant sends cases surging again across the U.S. Federal officials have reported a 20-fold increase in orders for the drugs since mid-July.
- COVID case rates hit new high for England, study finds - April 7, 2022
- Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
- SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
- Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022